Oncolytics Biotech® Reports Interim Results from Phase 1/2 GOBLET Study Showing a 70% Objective Response Rate in Pancreatic Cancer at the SITC Annual Meeting
We use cookies to improve your experience on our site, to show you personalized advertising, and as otherwise described in our Cookie Policy
. To find out more, read our
Privacy Policy
and our
Cookie Policy.